Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986259 PK and Safety in Renal Impairment
NCT04237831Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2020
- Primary completion
- Jul 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of FA relaxin in heart failure (HF) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum Plasma Concentration at Day 8, Time to Reach Maximum Concentration at Day 8 and 7 more. Started Feb 2020; status: completed.
02
Drugs
FA relaxin
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT04237831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04237831.